These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Performance of Validated MicroRNA Biomarkers for Alzheimer's Disease in Mild Cognitive Impairment. Sandau US, Wiedrick JT, Smith SJ, McFarland TJ, Lusardi TA, Lind B, Harrington CA, Lapidus JA, Galasko DR, Quinn JF, Saugstad JA. J Alzheimers Dis; 2020; 78(1):245-263. PubMed ID: 32955460 [Abstract] [Full Text] [Related]
3. MicroRNAs in Human Cerebrospinal Fluid as Biomarkers for Alzheimer's Disease. Lusardi TA, Phillips JI, Wiedrick JT, Harrington CA, Lind B, Lapidus JA, Quinn JF, Saugstad JA. J Alzheimers Dis; 2017; 55(3):1223-1233. PubMed ID: 27814298 [Abstract] [Full Text] [Related]
4. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Galasko D, Chang L, Motter R, Clark CM, Kaye J, Knopman D, Thomas R, Kholodenko D, Schenk D, Lieberburg I, Miller B, Green R, Basherad R, Kertiles L, Boss MA, Seubert P. Arch Neurol; 1998 Jul; 55(7):937-45. PubMed ID: 9678311 [Abstract] [Full Text] [Related]
12. The effect of APOE genotype on the delivery of DHA to cerebrospinal fluid in Alzheimer's disease. Yassine HN, Rawat V, Mack WJ, Quinn JF, Yurko-Mauro K, Bailey-Hall E, Aisen PS, Chui HC, Schneider LS. Alzheimers Res Ther; 2016 Jun 30; 8():25. PubMed ID: 27358067 [Abstract] [Full Text] [Related]
13. Analysis of Cerebrospinal Fluid and [11C]PIB PET Biomarkers for Alzheimer's Disease with Updated Protocols. Wang MJ, Yi S, Han JY, Park SY, Jang JW, Chun IK, Giau VV, Bagyinszky E, Lim KT, Kang SM, An SS, Park YH, Youn YC, Kim S. J Alzheimers Dis; 2016 May 06; 52(4):1403-13. PubMed ID: 27163824 [Abstract] [Full Text] [Related]
14. Association between Cerebrospinal Fluid Biomarkers for Alzheimer's Disease, APOE Genotypes and Auditory Verbal Learning Task in Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Disease. Mandecka M, Budziszewska M, Barczak A, Pepłońska B, Chodakowska-Żebrowska M, Filipek-Gliszczyńska A, Nesteruk M, Styczyńska M, Barcikowska M, Gabryelewicz T. J Alzheimers Dis; 2016 Jul 29; 54(1):157-68. PubMed ID: 27472875 [Abstract] [Full Text] [Related]
17. Proteomic analysis of cerebrospinal fluid in Alzheimer's disease: wanted dead or alive. Oláh Z, Kálmán J, Tóth ME, Zvara Á, Sántha M, Ivitz E, Janka Z, Pákáski M. J Alzheimers Dis; 2015 Jul 29; 44(4):1303-12. PubMed ID: 25428253 [Abstract] [Full Text] [Related]
18. Associations between cerebral small-vessel disease and Alzheimer disease pathology as measured by cerebrospinal fluid biomarkers. Kester MI, Goos JD, Teunissen CE, Benedictus MR, Bouwman FH, Wattjes MP, Barkhof F, Scheltens P, van der Flier WM. JAMA Neurol; 2014 Jul 01; 71(7):855-62. PubMed ID: 24818585 [Abstract] [Full Text] [Related]
19. Genetic variants of GSK3B are associated with biomarkers for Alzheimer's disease and cognitive function. Kettunen P, Larsson S, Holmgren S, Olsson S, Minthon L, Zetterberg H, Blennow K, Nilsson S, Sjölander A. J Alzheimers Dis; 2015 Jul 01; 44(4):1313-22. PubMed ID: 25420549 [Abstract] [Full Text] [Related]
20. Factors that influence the levels of cerebrospinal fluid biomarkers in memory clinic patients. Knapskog AB, Eldholm RS, Braekhus A, Engedal K, Saltvedt I. BMC Geriatr; 2017 Sep 11; 17(1):210. PubMed ID: 28893185 [Abstract] [Full Text] [Related] Page: [Next] [New Search]